Condition: Japanese Encephalitis Virus Disease · Sponsor: SK Bioscience Co., Ltd.
This is a 2-Stage, Phase I/II Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)
This description comes directly from the study's public registry record.
Sejun Oh · 82-2-2008-2200 · sejunoh@sk.com
Always discuss trial participation with your own doctor first.
| Nucleus Network - Brisbane (Q Pharm) | Brisbane, Australia | Recruiting |
| Nucleus Network - Melbourne | Melbourne, Australia | Recruiting |
| New Zealand Clinical Research | Christchurch, Central City, New Zealand | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06680128